Nature Medicine shared on X:
“Refining neoadjuvant immunotherapy for resectable Non- Small Cell Lung Cancer (NSCLC):
Perioperative approaches are expanding, and new data show feasibility of co-targeting PD-1 and LAG-3.
News and Views from Christine Lovly, Misty Dawn Shields and Vanderbilt University Medical Center.”
Additional information.
Source: Nature Medicine/X